Innovation Ltd Panacea Sells 80,554 Shares of Atara Biotherapeutics (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) major shareholder Innovation Ltd Panacea sold 80,554 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $6.07, for a total value of $488,962.78. Following the completion of the transaction, the insider owned 1,324,446 shares of the company’s stock, valued at $8,039,387.22. This represents a 5.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Atara Biotherapeutics Price Performance

Shares of NASDAQ:ATRA opened at $4.62 on Friday. Atara Biotherapeutics, Inc. has a 1 year low of $4.25 and a 1 year high of $19.15. The company has a market cap of $33.31 million, a P/E ratio of 2.12 and a beta of -0.41. The stock’s fifty day moving average price is $14.60 and its 200-day moving average price is $13.09.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.51. The business had revenue of $3.45 million during the quarter, compared to analyst estimates of $2.74 million. Atara Biotherapeutics had a negative return on equity of 41.78% and a net margin of 15.40%. On average, sell-side analysts anticipate that Atara Biotherapeutics, Inc. will post -10.39 earnings per share for the current year.

Analyst Upgrades and Downgrades

ATRA has been the subject of a number of research analyst reports. New Street Research set a $6.00 target price on shares of Atara Biotherapeutics in a research report on Tuesday. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $6.00 price objective (down previously from $25.00) on shares of Atara Biotherapeutics in a report on Tuesday. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Atara Biotherapeutics in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Atara Biotherapeutics presently has an average rating of “Reduce” and a consensus target price of $6.00.

Hedge Funds Weigh In On Atara Biotherapeutics

A number of institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP purchased a new position in Atara Biotherapeutics during the second quarter valued at $327,000. Mackenzie Financial Corp raised its stake in shares of Atara Biotherapeutics by 183.5% in the third quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company’s stock worth $914,000 after buying an additional 41,302 shares during the period. Vanguard Group Inc. raised its stake in shares of Atara Biotherapeutics by 6.6% in the third quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock worth $2,915,000 after buying an additional 12,677 shares during the period. GSA Capital Partners LLP lifted its position in shares of Atara Biotherapeutics by 33.8% during the 3rd quarter. GSA Capital Partners LLP now owns 26,213 shares of the biotechnology company’s stock valued at $376,000 after buying an additional 6,622 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Atara Biotherapeutics during the 2nd quarter valued at approximately $31,000. 70.90% of the stock is owned by institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.